The Technical AnalystExchange: HKSE Sector: Healthcare Industry: Biotechnology
Immunotech Biopharm Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.88% HKD3.43
America/New_York / 3 mai 2024 @ 04:08
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 765.02 mill |
| EPS: | -0.700 |
| P/E: | -4.90 |
| Earnings Date: | Mar 28, 2024 |
| SharesOutstanding: | 514.58 mill |
| Avg Daily Volume: | 0.0397 mill |
| RATING 2024-05-03 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | n/a | n/a | n/a | |||
| Asset | n/a | |||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.90 | sector: PE 34.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.14x |
| Company: PE -4.90 | industry: PE 35.62 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
HKD-0.817 (-123.82%) HKD-4.25 |
| Date: 2024-05-03 |
| Expected Trading Range (DAY) |
|---|
|
HKD 3.22 - 3.64 ( +/- 6.18%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | HKD3.43 (0.88% ) |
| Volume | 0.0360 mill |
| Avg. Vol. | 0.0397 mill |
| % of Avg. Vol | 90.66 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 6978.HK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
6978.HK
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for the prevention of postsurgical recurrence of liver cancer. The company is also conducting pre-clinical and clinical trial studies for EAL to treat lung cancer, glioma, gastric cancer, and colorectal cancer. In addition, it develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia; and TCR-T cell series products to treat solid tumors. The company was founded in 2006 and is headquartered in Beijing, the People's Republic of China.